Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][8]. Core Viewpoints - The report continues to recommend the innovative pharmaceutical and medical device industry chain, highlighting a selection of A-share and H-share stocks with an "Overweight" rating [2][8][11]. - The performance of the pharmaceutical sector in December 2025 was weaker than the broader market, with the SW Pharmaceutical Biotechnology index declining by 4.1% compared to a 2.1% increase in the Shanghai Composite Index [18][30]. - The report notes that the premium level of the pharmaceutical sector relative to the entire A-share market is currently at a normal level, with a relative premium rate of 63.2% as of December 31, 2025 [29][32]. Summary by Sections A-Share Recommendations - The report lists the following A-share stocks with an "Overweight" rating: - 恒瑞医药 (Hengrui Medicine) - 科伦药业 (Kelun Pharmaceutical) - 华东医药 (East China Pharmaceutical) - 恩华药业 (Enhua Pharmaceutical) - 特宝生物 (Tebao Biological) - 京新药业 (Jingxin Pharmaceutical) - 益方生物 (Yifang Biological) - 药明康德 (WuXi AppTec) - 泰格医药 (Tigermed) - 乐普医疗 (Lepu Medical) - 联影医疗 (United Imaging) - 微电生理 (Microelectrophysiology) [8][9]. H-Share Recommendations - The report maintains an "Overweight" rating for the following H-share stocks: - 翰森制药 (Hansoh Pharmaceutical) - 三生制药 (3SBio) - 科伦博泰生物 (Kelun-Botai Biological) - 康方生物 (CanSino Biologics) - 映恩生物 (InnoCare Pharma) - 百济神州 (BeiGene) [11][12]. Performance Analysis - The report indicates that the 国泰海通医药 monthly portfolio outperformed the pharmaceutical index in December 2025, with an average decline of 1.8% compared to a 3.9% decline in the overall pharmaceutical index [14][15]. - The report highlights the best-performing stocks in December 2025, with 泰格医药 (Tigermed) increasing by 11.2%, 特宝生物 (Tebao Biological) by 7.5%, and 惠泰医疗 (Huitai Medical) by 3.9% [15][18].

港股开盘，恒生指数涨0.34%，恒生科技指数涨0.58%。个股方面，壁仞科技涨82.14%，新意网集团涨 6.3%，MIRXES-B涨4.45%，金风科技涨4.4%，泰格医药涨3.29%；五一视界跌3.02%。 ...

Core Insights - The CXO sector in A/H shares shows signs of fundamental recovery ahead of expectations in 2025 after three years of valuation downgrades [1] - The recovery is uneven, with the clinical CRO segment still facing challenges, indicating a divergence in industry recovery [1][7] Group 1: Financial Performance - WuXi AppTec (药明康德) reported a revenue of 32.857 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [1] - The company had a backlog of orders amounting to 59.880 billion yuan as of September 2025, reflecting a 37.2% year-on-year growth [1] - The average price of clinical research services in China has decreased by approximately 30% since 2022, impacting gross and net profit margins [2] Group 2: Order Fulfillment and Business Model - The business model of CXO leads to a natural lag in order fulfillment, with revenue recognition often taking multiple quarters or years [2] - WuXi AppTec's backlog at the end of 2024 was 49.310 billion yuan, 1.26 times its revenue for that year, indicating visible future revenue growth potential [2] - The order-to-revenue ratio is crucial for assessing conversion efficiency, with a healthy range identified between 1.2 to 1.3 times [3] Group 3: Market Dynamics and Challenges - The global pharmaceutical R&D investment continues to grow, but structural fluctuations are evident, particularly among innovative drug startups [1] - The clinical CRO segment is heavily influenced by funding constraints and project strategy adjustments, leading to a situation where project numbers increase but individual project outputs decline [8] - The international expansion of clinical CROs raises higher standards for organizational capability and compliance, making short-term recovery challenging [8] Group 4: Emerging Opportunities - The global expansion of GLP-1 and related indications has led to unexpected order increases in upstream peptide and related processes, maintaining high demand in 2025 [9] - Core stock Novartis Bio (诺泰生物) achieved a revenue of 1.527 billion yuan in the first three quarters of 2025, with a net profit of 445 million yuan, reflecting a year-on-year growth of 21.95% and 26.92% respectively [9] - The market for cell and gene therapy (CGT) is still growing, but profitability remains elusive, with significant investments required before becoming a core profit driver [10][11]

Group 1: Core Insights - The report maintains a strong market rating for the pharmaceutical industry, indicating a clear upward trend driven by recovering demand and improved performance in the CXO sector [1][2] - The CXO sector has shown significant stock price increases, with some companies experiencing nearly 100% growth since the beginning of 2025, driven by the innovative drug market and a recovery in orders [3][6] Group 2: CXO Sector Analysis - The CXO sector's overall revenue increased by 11.8% year-on-year in the first three quarters of 2025, with a notable profit increase of 58.1% [13] - External demand for CXO services has rebounded, with significant order growth from leading CDMO companies, indicating a clear recovery trend [22][31] - Internal demand for CXO services has lagged behind external demand, but there are signs of strong growth in domestic innovative drug projects and increased investment in the domestic market [3][22] Group 3: Life Sciences Upstream - The life sciences upstream sector has seen a 37.7% increase in stock prices year-to-date, outperforming the pharmaceutical and biotechnology index by 18% [3] - Revenue for the upstream sector increased by 8.8% year-on-year in the first three quarters of 2025, with net profit rising by 27.7% [3] Group 4: Investment Recommendations - The report suggests a strategic investment focus on companies such as WuXi AppTec, WuXi Biologics, and Tigermed, while also highlighting more flexible investment options like Zhaoyan New Drug and Nossan [3]

Market Performance - The Hong Kong stock market closed early due to the New Year holiday, with the Hang Seng Index rising 27.77% for the year, closing at 25,630.54 points [1] - The Technology Index increased by 23.45%, closing at 5,515.98 points, while the National Enterprises Index rose by 22.27%, closing at 8,913.68 points [1] Daily Market Movement - On the last trading day of the year, the market showed light trading activity, with the Hang Seng Index down 0.87%, the Technology Index down 1.12%, and the National Enterprises Index down 0.86% [3] Sector Highlights Film and Entertainment - Film stocks led the market, with major gains from companies like Dama Entertainment (+5.56%), Maoyan Entertainment (+3.12%), and Huayi Brothers (+1.59%) [8] - The 2025 New Year box office reached 5.245 billion yuan, marking an eight-year high, with a 76.35% year-on-year increase in November box office [9] Aviation - Airline stocks surged due to increased travel demand for the New Year holiday, with China Eastern Airlines (+4.92%), China Southern Airlines (+4.30%), and Air China (+3.36%) showing significant gains [10] - Domestic flight ticket bookings exceeded 2.71 million, a 35% year-on-year increase, with average ticket prices rising by 6.7% [11] Cryptocurrency - Cryptocurrency-related stocks saw gains, with HashKey Holdings (+11.33%) and OSL Group (+4.29%) benefiting from favorable policy developments regarding digital currency [12] - The new digital RMB framework will take effect on January 1, 2026, enhancing market expectations for compliant cryptocurrency ecosystems [13] Robotics - Robotics stocks faced pressure, with MicroPort Robotics (-8.72%) and DJI (-4.29%) declining, despite the establishment of a new standardization committee for humanoid robots [14][15] Pharmaceuticals - Pharmaceutical stocks continued to struggle, with companies like Fonda Holdings (-1.96%) and WuXi Biologics (-1.93%) showing declines [17] - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 participants, including major Chinese pharmaceutical firms [18] Individual Stock Movements - Xuanwu Cloud saw a significant intraday rise of over 13% following news of a strategic investment from Hantang Mingyuan [19] - Boke Vision Cloud experienced a rise of over 9% after its largest shareholder extended the lock-up period for shares [20]

Core Viewpoint - The Hong Kong pharmaceutical market is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (159570) declining by 1.14% and over 25% from its previous high, despite a significant trading volume of over 1.44 billion yuan [1][4]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen a three-day decline, reaching a new low, with a total trading volume exceeding 14.4 billion yuan [1]. - As of December 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) is over 21.9 billion yuan, leading among its peers [1]. - Major stocks within the ETF, such as King’s Bio and Kelun-Bio, have experienced declines, with King’s Bio dropping over 3% [4][5]. Group 2: IPO Activity - On December 30, Insilico Medicine, a generative AI-driven biopharmaceutical company, successfully listed on the Hong Kong Stock Exchange, marking it as the first AI biopharmaceutical company to do so under the main board listing rules [3]. - The IPO raised a total of 2.277 billion Hong Kong dollars, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [3]. Group 3: Industry Trends - The upcoming J.P. Morgan Healthcare Conference in January 2026 is expected to attract over 8,000 global participants, featuring more than 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6]. - Key trends highlighted for the industry include the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces from China [7]. Group 4: Investment Insights - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs and technology platforms from China, with average total deals from China reaching 2.756 billion USD compared to 1.289 billion USD from overseas [8]. - The pressure from patent expirations, estimated at around 300 billion USD in sales, is driving MNCs to seek high-potential assets in China, particularly in advanced fields like ADCs and cell therapies [9]. - MNCs are shifting their focus from merely acquiring products to obtaining platforms and technologies that can yield new molecules, indicating a strategic evolution in their investment approach [10]. Group 5: Key Investment Areas - Key investment areas include ADCs, GLP-1 for metabolic diseases, bispecific antibodies, and neuroscience, with a focus on companies that can deliver competitive clinical data and innovative platforms [12][13].

证券之星消息，12月30日医疗服务板块较上一交易日下跌0.73%，昭衍新药领跌。当日上证指数报收于 3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920670 | 数字人 | 15.87 | 4.20% | 5.91万 | 9396.08万 | | 600568 | ST中珠 | 2.52 | 2.86% | 22.48万 | 5686.21万 | | 300347 | 泰格医药 | 56.63 | 1.27% | 9.14万 | 5.16亿 | | 688621 | 阳光诺和 | 64.18 | 1.20% | 1.74万 | 1.10亿 | | 688131 | 皓元医药 | 72.54 | 0.96% | 2.24万 | 1.62亿 | | 301096 | 百诚医药 | 57.75 | 0.70% | 3.10万 | 1.78亿 | | 300363 | 博腾股份 | 23.45 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 19 companies, including Shimai Pharmaceutical, which must clarify the progress of state-owned shareholder management procedures and other matters related to its overseas listing application [1]. Group 1: Company Requirements - Shimai Pharmaceutical needs to provide details on the progress of state-owned shareholders fulfilling state-owned stock identification and management procedures [2]. - The company must explain the pricing basis and reasons for price differences in past capital increases and share transfers, and confirm the legality and compliance of its establishment and share changes [3]. - It is required to clarify whether the shares held by shareholders participating in the "full circulation" are subject to pledges, freezes, or other rights defects [4]. Group 2: Financial Performance - Shimai Pharmaceutical has not generated any drug sales revenue or milestone payments, with total other income of approximately 14.65 million yuan, 6.62 million yuan, and 2.28 million yuan for 2023, 2024, and the first half of 2025, respectively [4]. - The company reported losses of 74.94 million yuan, 59.90 million yuan, and 25.42 million yuan for the years 2023, 2024, and the first half of 2025, with cumulative losses exceeding 160 million yuan [5]. - The primary reason for ongoing losses is the lack of commercialized products, with income mainly from government subsidies and investment returns, which are insufficient to cover high R&D and operational costs [5]. Group 3: R&D Expenditure - R&D expenses for the company were 76.11 million yuan, 53.38 million yuan, and 22.39 million yuan for 2023, 2024, and the first half of 2025, respectively, indicating a significant decline in R&D investment [6]. - The R&D expenditure for the core product SMET12 decreased by 73.7% in the first half of 2025 compared to the same period in 2024, raising concerns about the development of core products [6]. Group 4: Cash Flow and Financing - As of June 30, 2025, the company's cash and cash equivalents were only 85.74 million yuan, while the average annual R&D expenditure was around 60 million yuan [7]. - By September 30, 2025, cash and cash equivalents sharply declined to 5.71 million yuan, indicating a rapid depletion of funds [8]. - The company has completed three rounds of financing, with a post-Series C valuation of 2.23 billion yuan, supported by investors such as Betta Pharmaceuticals and Tigermed [9]. Group 5: Market Potential - The global TCE market is projected to reach approximately $3 billion by 2024, with a compound annual growth rate (CAGR) of 40% expected to grow to $121.1 billion by 2035 [10]. - The Chinese TCE market is anticipated to reach 700 million yuan by 2024, with a CAGR of 63.8% expected to grow to 159.6 billion yuan by 2035 [10]. Group 6: Shareholder Structure and Future Plans - The company's actual controller, Xiao Zuoxiang, holds 53.2% of the shares, making him the controlling shareholder, while Betta Pharmaceuticals holds 4.75% through its subsidiary [11]. - The company plans to use the funds raised from its Hong Kong listing primarily for clinical development of core products, optimization of technology platforms, new product development, and operational funding [11].

Core Viewpoint - The China Securities Regulatory Commission has issued supplementary material requirements for 19 companies, including Shimai Pharmaceutical, which must clarify the progress of state-owned shareholders in fulfilling state asset management procedures [1][2]. Group 1: Company Overview - Shimai Pharmaceutical was established in 2017 and focuses on the development of T-cell engagers (TCEs), with four clinical-stage candidates: DNV3, SMET12, CMD011, and CMDE005 [2]. - The company has received three rounds of financing, with a post-Series C valuation of 2.23 billion RMB, driven by investor optimism regarding the TCE therapy market [8]. Group 2: Financial Performance - The company reported no drug sales or milestone payments during the reporting period, with other income of approximately 14.65 million RMB in 2023, 6.62 million RMB in 2024, and 2.28 million RMB in the first half of 2025, primarily from government subsidies and investment income [3]. - Shimai Pharmaceutical's losses were 74.94 million RMB in 2023, 59.90 million RMB in 2024, and 25.42 million RMB in the first half of 2025, totaling over 160 million RMB in cumulative losses [3][4]. - The company has indicated that it may never achieve or maintain profitability, as it has not yet commercialized any products [3]. Group 3: Research and Development - Research and development expenses were 76.11 million RMB in 2023, 53.38 million RMB in 2024, and 22.39 million RMB in the first half of 2025, showing a significant decline that raises concerns about the development of core products [4][5]. - The R&D spending for the core product SMET12 decreased by 73.7% to 2.14 million RMB in the first half of 2025 compared to the same period in 2024 [5]. Group 4: Market Potential - The global TCE market is projected to reach approximately 3 billion USD by 2024, with a compound annual growth rate of 40% expected to grow to 121.1 billion USD by 2035 [8]. - The Chinese TCE market is expected to reach 700 million RMB by 2024, with a compound annual growth rate of 63.8% projected to grow to 159.6 billion RMB by 2035 [8]. Group 5: Funding and Cash Flow - The company has utilized 62.32 million RMB and 45.23 million RMB for financial investments in 2024 and the first half of 2025, respectively, despite ongoing losses [6]. - As of June 30, 2025, the company's cash and cash equivalents were only 5.71 million RMB, a significant decrease from 85.74 million RMB just three months prior [7].

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].